Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner

Molecular Cancer Research

Volumn 3, Issue 5, 2005, Pages 287-296

  Min, Junxia ^a   Van Veldhoven, Paul P ^b   Zhang, Lei ^c,d   Hanigan, Marie H ^c   Alexander, Hannah ^a   Alexander, Stephen ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; DIMETHYLSPHINGOSINE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; SPHINGOSINE 1 PHOSPHATE LYASE; SPHINGOSINE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; CELL STRAIN HEK293; CHEMOTHERAPY; CONTROLLED STUDY; DICTYOSTELIUM DISCOIDEUM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PRIORITY JOURNAL;

ALDEHYDE-LYASES; ANTINEOPLASTIC AGENTS; CELL LINE; CELL PROLIFERATION; CISPLATIN; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA, SMALL INTERFERING;

DICTYOSTELIUM DISCOIDEUM;

EID: 18544390682     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-04-0197     Document Type: Article

References (35)

1. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
2. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998;34:1535-42.
3. Li GC, Alexander H, Schneider N, Alexander S. Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium. Microbiology 2000;146:2219-27.
4. Spiegel S, Milstien S. Sphingosine 1-phosphate, a key cell signaling molecule. J Biol Chem 2002;277:25851-4.
5. Le Stunff H, Coursol S, Milstien S, Spiegel S. Sphingosine-1-phosphate metabolism in mammalian cell signalling. Lipid Metab Membrane Biogenesis 2004;6:313-35.
6. Pyne S. Cellular signaling by Sphingosine and Sphingosine 1-phosphate. Their opposing roles in apoptosis. In: Quinn A, Kagan A, editors. Phospholipid metabolism in apoptosis. New York: Kluwer Academic/Plenum; 2002. p. 245-68.
7. Min J, Stegner A, Alexander H, Alexander S. Overexpression of sphingosine-1-phosphate lyase or inhibition of Sphingosine kinase in Dictyostelium discoideum results in a selective increase in sensitivity to platinum based chemotherapy drugs. Eukaryot Cell 2004;3:795-805.
8. Min J, Traynor D, Stegner A, et al. Sphingosine kinase regulates the sensitivity of Dictyostelium discoideum cells to the anticancer drug cisplatin. Eukaryot Cell 2005;4:178-89.
9. Edsall LC, Van Brooklyn JR, Cuvillier O, Kleuser B, Spiegel S. N,N-dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of Sphingosine 1-phosphate and ceramide. Biochemistry 1998;37:12892-8.
10. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 1996;381:800-3.
11. Gijsbers S. Metabolism and biological activities of sphingosine-1- phosphate. Acta Biomedica Lovaniensia. Leuven University Press; 2002.
12. Ikeda M, Kihara A, Igarashi Y. Sphingosine-1-phosphate lyase SPL is an endoplasmic reticulum-resident, integral membrane protein with the pyridoxal 5′-phosphate binding domain exposed to the cytosol. Biochem Biophys Res Commun 2004;325:338-43.
13. Yatomi Y, Igarashi Y, Yang L, et al. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem (Tokyo) 1997;121:969-73.
14. Reiss U, Oskouian B, Zhou J, et al. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J Biol Chem 2004;279:1281-90.
15. Kyriakis J, Liu H, Chadee D. Activation of SAPKs/JNK and p38s in vitro. In: Seger R, editor. MAP kinase signaling protocols. Totowa (NJ): Humana Press; 2004. p. 62-88.
16. Losa JH, Cobo CP, Viniegra JG, Sanchez-Arevalo Lobo VJ, Ramon y Cajal S, Sanchez-Prieto R. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003;22:3998-4006.
17. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003;278:19245-56.
18. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J Biol Chem 2003;278:23432-40.
19. Zhao S, Yang YN, Song JG. Ceramide induces caspase-dependent and -independent apoptosis in A-431 cells. J Cell Physiol 2004;199:47-56.
20. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004;10:125-9.
21. Hanigan MH, Deng M, Zhang L, Taylor PT Jr, Lapus MG. Stress response inhibits the nephrotoxicity of cisplatin. Am J Physiol Renal Physiol 2004.
22. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003;14:1-10.
23. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-4.
24. Xia P, Gamble JR, Wang L, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000;10:1527-30.
25. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9.
26. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-16.
27. Lacombe L, Orlow I, Reuter VE, et al. Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int J Cancer 1996;69:110-3.
28. Steck PA, Ligon AH, Cheong P, Yung WK, Pershouse MA. Two tumor suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromosomes Cancer 1995;12:255-61.
29. Petersen S, Wolf G, Bockmuhl U, Gellen K, Dietel M, Petersen I. Allelic loss on chromosome 10q in human lung cancer: association with rumour progression and metastatic phenotype. Br J Cancer 1998;77:270-6.
30. Payne SG, Milstien S, Barbour SE, Spiegel S. Modulation of adaptive immune responses by sphingosine-1-phosphate. Semin Cell Dev Biol 2004;15:521-7.
31. Kimura T, Boehmier AM, Seitz G, et al. The sphingosine 1-phosphate receptor agonist FTY720 supports CXCR4-dependent migration and bone marrow homing of human CD34(+) progenitor cells. Blood 2004;103:4478-86.
32. Van Veldhoven PP, Gijsbers S, Mannaerts GP, Vermeesch JR, Brys V. Human sphingosine-1-phosphate lyase: cDNA cloning, functional expression studies and mapping to chromosome 10q22(1). Biochim Biophys Acta 2000;1487:128-34.
33. Van Veldhoven PP. Sphingosine-1-phosphate lyase. In: Methods in enzymology. Academic Press; 1999. p. 244-54.
34. Takahashi K, Seki T, Nishikawa K, et al. Antitumor activity and toxicity of serum protein-bound platinum formed from cisplatin. Jpn J Cancer Res 1985;76:68-74.
35. Yotsuyanagi T, Ohta N, Futo T, Ito S, Chen DN, Ikeda K. Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfarin binding. Chem Pharm Bull (Tokyo) 1991;39:3003-6.